Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
暂无分享，去创建一个
C. Tournigand | K. Bensalah | J. Bernhard | J. Zucman‐Rossi | C. Sautès-Fridman | W. Fridman | Cheng-ming Sun | Guillaume Lacroix | A. De la taille | S. Oudard | G. Pignot | G. Gravis | N. Houédé | N. Doumerc | P. Barthélémy | L. Fournier | T. Tricard | S. Caruso | P. Beuzeboc | X. Cathelineau | C. Chevreau | C. Thibault-Carpentier | V. Verkarre | P. Paparel | B. Laguerre | D. Maillet | A. Méjean | O. Huillard | M. Meylan | Y. Vano | R. Elaidi | M. Bennamoun | D. Borchiellini | M. Cancel | E. Coquan | E. Braychenko | Letuan Phan | D. Pannier | T. Waeckel | M. Moreira | M. Gross‐Goupil | Antoine Bougouïn | Cheng-Ming Sun | L. Phan | M. Gross-Goupil | T. Tricard